GENE ONLINE|News &
Opinion
Blog

Go Prime
Mounting Criticisms of FDA’s Accelerated Approval Pathway Could Prompt Changes to the System
2022-08-25
NIH Provides $23 Million to Fund Telehealth Cancer Care Research
2022-08-22
2026: The Promise of Synthetic Biology
2022-08-11
How Governments Around the World Should Respond to the Mounting Costs of Gene and Cell Therapy?
2022-07-08
America’s Ongoing Battle For Lower Insulin Prices
2022-06-23
Convergence, Communication and Commercialization, The Cornerstones In Emerging Regulatory Trends
2022-05-24
The FDA Issued its First Formal Warning to Companies Selling Delta-8 THC Products
2022-05-05
These Two Companies are Helping Push Denmark to the Forefront of Biotech
2022-04-21
Bio-Europe Spring: 2022 Europe Ophthalmic Medication Market Skyrockets
2022-04-20
Compensating for OxyContin: The Harm from Pharma
2022-04-12
Insider: Groundbreaking Malaria Vaccine Reinvigorates the Fight against Disease
2022-03-30
Market Insight on FDA-approvals: Rise of First-in-class and Regenerative Innovations
2022-03-17
From Forbidden Drugs to Psychotropic Cures: A “Psychedelic Boom” Breaks New Ground in Treating Mental Illnesses
2022-03-08
Top 10 Biotech IPOs on NASDAQ in 2021
2022-01-19
Sex Dimorphism in Obesity and the Impact of Estrogen Hormone Therapy on Cardiometabolic Health
2022-01-17
1 2 3 10
LATEST
AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan
2022-09-28
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
2022-09-28
Arsenal Biosciences Announced Another $70 million Collaboration, This Time With Genentech
2022-09-27
Sciwind Biosciences And SynerK Join Forces To Develop siRNA Therapeutics
2022-09-27
Acticor Enrolls First Patient in Phase 2/3 Stroke Treatment Study
2022-09-27
Daiichi Sankyo Wins Approval For Cancer Treatment in Japan
2022-09-26
Seagen Strikes Potential $650 million Deal with LAVA Therapeutics for Cancer Treatment
2022-09-26
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!